Highlights
1 patentProfile claimed by owner
About
Target-inhibiting Anticancer Drugs
Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics. The company focuses on developing drugs that inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells. Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.
Identity
| Name | Metabomed |
|---|---|
| Slug | metabomed |
| Type / kind | startup |
| Crunchbase ID | metabomed |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL-FiIsKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Yavne |
| HQ address | HaKishon Street 18, Yavne, Israel |
Web & social
| https://www.linkedin.com/company/9341600 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharma-companiestargeted-therapyoncologybiotechnologybiopharmaceuticalcancerdrug-discoverygenomics
Funding
| Total raised | $30.5M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}